A new treatment

Read More

Our Goal

Ischemic stroke is the second leading cause of death and a major cause of disability. Avilex Pharma investigates a novel principle in treatment to meet this major medical need.
Avilex_Banner_2

Science

Avilex Pharma develops novel inhibitors of PDZ domain proteins to target a range of unmet medical needs. Our lead candidate AVLX-144 is a drug candidate for the treatment of ischemic stroke.

Read More
Avilex_Company_Home250x160

The Company

Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Ass. Prof. Anders Bach of the Department of Drug Design and Pharmacology.

Read More
gs_picture

Latest News

Avilex Pharma and key partners receive an investment of DKK 20 mill. (total budget DKK 26 mill. / $4.0 mill.) from Innovation Fund Denmark to bring AVLX-144 to the clinic and develop a new PET marker.

Read More
© Copyright 2019 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK